Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Phase 3

Completed

• Conditions: Leukemia, Lymphocytic, Acute

• Registration Number: NCT00483132
• Lead Sponsor: French Innovative Leukemia Organisation

Brief Summary

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.

High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).

Detailed Description

Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Study Timeline

• Study Start: 1994-09
• Study Completion: 2002-04
• Status Verified: 2007-06
• Study First Submitted: 2007-06-05
• Study First Submitted QC: 2007-06-05
• Last Update Submitted: 2007-06-05
• Study First Posted: 2007-06-06
• Last Update Posted: 2007-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 232

Inclusion Criteria

Not provided

Exclusion Criteria

• patients previously treated with a chemotherapy or alpha-interferon
• ALL 3 (burkitt like)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
overall survival	time to death

Secondary Outcome Measures

Name	Time	Method
Efficacy of study treatments	time to end of treatment

Trial Locations

Locations (1)

INorbert IFRAH; 🇫🇷 Angers, chu ANGERS, France